DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Controlled-release doxazosin as combination therapy in hypertension: the GATES study.

Author(s): Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A

Affiliation(s): Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. hblack@rush.edu

Publication date & source: 2006-03, J Clin Hypertens (Greenwich)., 8(3):159-66

Publication type: Multicenter Study; Randomized Controlled Trial

Doxazosin gastrointestinal therapeutic system (GITS) or placebo was added to the antihypertensive therapy of uncontrolled hypertensive patients in a prospective, randomized, double-blind trial. Patients received doxazosin GITS 4 mg/d (n=89) or placebo (n=86) for 6 weeks in addition to entry antihypertensive medication. Doxazosin GITS was increased to 8 mg/d after 2 or 4 weeks if patients did not respond (sitting blood pressure <140/90 mm Hg and 10/10-mm Hg decrease from baseline). Reductions from baseline in sitting and standing blood pressures were greater with doxazosin GITS than placebo at all time points (p</=0.017) except Week 1 sitting systolic pressure (p=0.068). The response rate was greater in the doxazosin GITS group (37.3%) than the placebo group (10.7%; p<0.001). With the exception of postural hypotension (7% compared with 0.0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents.

Page last updated: 2006-11-04

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017